Post-cycle and ancillaries compared

Tamoxifen vs raloxifene

Two estrogen receptor modulators, with each figure tied to its own label or trial.

The tamoxifen label calls tamoxifen a nonsteroidal antiestrogen, and the Evista label calls raloxifene an estrogen agonist/antagonist.1,2 The tamoxifen label gives a terminal elimination half-life of about 5 to 7 days, and the Evista label a plasma elimination half-life of 27.7 hours after oral dosing.1,2

The STAR trial compared them directly in 19,747 postmenopausal women, with tamoxifen 20 mg a day or raloxifene 60 mg a day over 5 years.3

FactTamoxifen (Nolvadex)Raloxifene
What it isA nonsteroidal antiestrogen that competes with estradiol for the estrogen receptor1An estrogen agonist/antagonist: an agonist in bone and, in preclinical data, an antagonist in uterine and breast tissue2
How it comesTablets of 10 mg and 20 mg, for oral administration1A 60 mg tablet for oral use2
Half-life
  • Terminal elimination half-life of about 5 to 7 days on the US label1
  • About 14 days for its metabolite N-desmethyl tamoxifen, at steady state in about 8 weeks1
Plasma elimination half-life of 27.7 hours after oral dosing, on the US label2
Studied doses
  • US label: 20 to 40 mg a day for breast cancer1
  • Prevention trial: 20 mg a day or placebo for 5 years, in 13,388 women at increased risk (6,681 on tamoxifen)5
  • US label: a 60 mg tablet orally once daily2
  • STAR trial: 60 mg a day over 5 years, against tamoxifen 20 mg a day, in 19,747 postmenopausal women3
StatusUS label: metastatic breast cancer in women and men, node-positive and node-negative breast cancer, DCIS after surgery and radiation, and lowering breast cancer incidence in women at high risk1. WADA lists it among anti-estrogenic substances (S4.2), prohibited at all times6US label: osteoporosis in postmenopausal women, and lowering invasive breast cancer risk in some postmenopausal women; no indication in men2. WADA lists it among anti-estrogenic substances (S4.2), prohibited at all times6

Get the app

Contents6
  1. 1The trials that compared them
  2. 2How they differ
  3. 3Logged in Milligram
  4. 4What is not known
  5. 5References
  6. 6Related pages

Last reviewed . Sources are listed below.

The trials that compared them

In the STAR trial, a double-blind randomised trial in postmenopausal women at increased 5-year breast cancer risk, there were 163 cases of invasive breast cancer with tamoxifen and 168 with raloxifene, a risk ratio of 1.02.3 The report gives 57 cases of noninvasive breast cancer with tamoxifen and 80 with raloxifene, a difference it calls not statistically significant, fewer thromboembolic events with raloxifene (risk ratio 0.70), 36 cases of uterine cancer with tamoxifen and 23 with raloxifene (risk ratio 0.62, 95% CI 0.35 to 1.08), and no difference in total deaths.3

A crossover study randomised 10 healthy men to 2 weeks each of tamoxifen at 10 and 20 mg a day and raloxifene at 60 and 120 mg a day; both raised LH, FSH and testosterone, and tamoxifen, but not raloxifene, lowered IGF-I.4

How they differ

The Evista label states that about 60% of an oral dose is absorbed but absolute bioavailability is 2% because of extensive presystemic glucuronide conjugation, and reports evidence that raloxifene is not metabolized by cytochrome P450 pathways.2 The tamoxifen label states that tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6.1

Logged in Milligram

  • Tamoxifen (Nolvadex): Too few people logged it to show a share.
  • Raloxifene: Too few people logged it to show a share.

Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.

What is not known

The Evista label states that raloxifene has not been adequately studied in men and speaks against its use in men, and the authors of the crossover study write that its neuroendocrine effects in men are poorly understood.2,4 The tamoxifen label states that the effects of age, gender and race on its pharmacokinetics have not been determined.1

References

  1. Mayne Pharma. TAMOXIFEN CITRATE tablet, film coated. Drug label, 2022. DailyMed label
  2. Eli Lilly and Company. EVISTA (raloxifene hydrochloride) tablet, prescribing information. Drug label, 2023. DailyMed label
  3. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Randomized trial, 2006. PMID 16754727
  4. Birzniece V, Sata A, Sutanto S, Ho KK. Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men. Randomized crossover study, 2010. PMID 20843951
  5. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Randomised trial, 1998. PMID 9747868
  6. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. Prohibited List, 2026. wada-ama.org